Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 6.25 GBX -0.79% Market Closed
Market Cap: 297.9m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allergy Therapeutics PLC
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Cash Interest Paid
ÂŁ4m
CAGR 3-Years
89%
CAGR 5-Years
66%
CAGR 10-Years
35%
GlaxoSmithKline PLC
LSE:GSK
Cash Interest Paid
ÂŁ660m
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
AstraZeneca PLC
LSE:AZN
Cash Interest Paid
$1.2B
CAGR 3-Years
18%
CAGR 5-Years
9%
CAGR 10-Years
9%
Verona Pharma PLC
NASDAQ:VRNA
Cash Interest Paid
$7.2m
CAGR 3-Years
249%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Cash Interest Paid
$81m
CAGR 3-Years
27%
CAGR 5-Years
9%
CAGR 10-Years
9%
Dechra Pharmaceuticals PLC
LSE:DPH
Cash Interest Paid
ÂŁ18.3m
CAGR 3-Years
31%
CAGR 5-Years
26%
CAGR 10-Years
14%
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
297.9m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.33 GBX
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Cash Interest Paid?
Cash Interest Paid
4m GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Cash Interest Paid amounts to 4m GBP.

What is Allergy Therapeutics PLC's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
35%

Over the last year, the Cash Interest Paid growth was 701%. The average annual Cash Interest Paid growth rates for Allergy Therapeutics PLC have been 89% over the past three years , 66% over the past five years , and 35% over the past ten years .

Back to Top